Publications

This infographic issued on 27 January 2023 provides a weekly traffic light report of the coronavirus (COVID-19) situation across Australia.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This Gaucher disease review considered 3 enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health.

This Gaucher disease review considered three enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This user guide explains to administrators how to use the My Aged Care service and support portal.

This document outlines the terms of use for the Government Provider Management System (GPMS). The GPMS allows aged care service providers to see their Star Ratings.

A list of National Health and Medical Research Council (NHMRC) projects and the committed funding.

Evaluation of the COAG Section 19(2) Exemptions Initiative – Improving Access to Primary Care in Rural and Remote Areas Final Report

This chart shows the structure of the Department of Health and Aged Care, including our divisions, branches, statutory office holders and high priority taskforces.

The meeting of the National Aged Care Advisory Council was held on 15 December 2022.

An update from the Council of Elders after their meeting on 8 and 9 December, 2022.

Information and advice for general practitioners and other medical practitioners about the COVID-19 MBS telehealth ‘established relationship’ requirement, including a clarification of exemptions.

This newsletter provides key health updates for Aboriginal and Torres Strait Islander households, communities and stakeholders.

Information on the new prescribed pattern of service 30/20 telephone rule, including relevant telephone attendance services. From 1 October 2022, GPs, Other Medical Practitioners and consultant physicians that claim relevant Medicare telephone items will be subject to the new rule.

This document answers some frequently asked questions the department has received from Commonwealth Home Support Programme (CHSP) service providers about Missing CHSP Client Migration process.

This document contains the surveillance case definition for Japanese encephalitis virus infection, which is nationally notifiable within Australia. State and territory health departments use this definition to decide whether to notify us of a case.

This guideline can help you to substantiate Child Dental Benefits Schedule (CDBS) services that you have claimed or that have been claimed through your provider number. You must also show that consent to dental services and costs has been obtained and recorded.

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. These documents provide a summary of the review findings and recommendations.

This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumer

This is an exposure draft of the proposed amendments to the Accountability Principles 2014 and Records Principles 2014 and the explanatory statement for these amendments. These amendments will support better provider governance and reporting arrangements.